Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01388764 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01388764: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01388764 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01388764, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability, and effects of L-Arginine on muscles in boys with dystrophinopathy on corticosteroids. Specifically, to see if L-arginine reduces muscle signal abnormalities on MRI done pre and post 30 days of L-arginine administration.
Interventions
- DRUG L-arginine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01388764
The ClinicalTrials.gov registry entry for NCT01388764 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-arginine is the first listed.
NCT01388764 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01388764 about?
NCT01388764 is a clinical study titled "Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids". The purpose of the study is to assess the safety, tolerability, and effects of L-Arginine on muscles in boys with dystrophinopathy on corticosteroids. Specifically, to see if L-arginine reduces muscle signal abnormalities on MRI done pre and post 30 days of L-arginine administration.
What is the current status of trial NCT01388764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2012-01. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01388764?
The interventions under investigation include: L-arginine (DRUG).
Who is sponsoring clinical trial NCT01388764?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.